OS Therapies Incorporated
OSTX
$2.00
$0.189.89%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 254.13% | 23.96% | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 56.91% | 1.59% | -- | -- | -- |
| Operating Income | -56.91% | -1.59% | -- | -- | -- |
| Income Before Tax | -14.00% | 17.15% | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.00% | 17.15% | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.00% | 17.15% | -- | -- | -- |
| EBIT | -56.91% | -1.59% | -- | -- | -- |
| EBITDA | -56.99% | -1.65% | -- | -- | -- |
| EPS Basic | 31.93% | 44.99% | -- | -- | -- |
| Normalized Basic EPS | 38.97% | 44.67% | -- | -- | -- |
| EPS Diluted | 31.93% | 44.99% | -- | -- | -- |
| Normalized Diluted EPS | 38.97% | 44.67% | -- | -- | -- |
| Average Basic Shares Outstanding | 74.38% | 42.45% | -- | -- | -- |
| Average Diluted Shares Outstanding | 74.38% | 42.45% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |